Document Detail

Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.
MedLine Citation:
PMID:  16186794     Owner:  NLM     Status:  MEDLINE    
A total of 30-50% of early breast cancer (EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite standard adjuvant systemic treatment. A means to better predict clinical outcome is needed to optimize and individualize therapeutic decisions. To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization-time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured and fractionated serum samples were incubated with IMAC30 and CM10 ProteinChip arrays. Several protein peaks were differentially expressed according to clinical outcome. By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. The 5-year metastasis-free survival in 'good prognosis' and 'poor prognosis' patients as defined using the multiprotein index were strikingly different (83 and 22%, respectively; P<0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, the latter retained the strongest independent prognostic significance for metastatic relapse. Major components of the multiprotein index included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1. Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC.
A Gonçalves; B Esterni; F Bertucci; R Sauvan; C Chabannon; M Cubizolles; V J Bardou; G Houvenaegel; J Jacquemier; S Granjeaud; X-Y Meng; E T Fung; D Birnbaum; D Maraninchi; P Viens; J-P Borg
Related Documents :
8336194 - Prognostic factors in waldenström's macroglobulinemia: a report of 167 cases.
14690164 - Laryngeal carcinoma--multivariate analysis of prognostic factors in 1252 consecutive pa...
1333064 - A formula for predicting the risk of a positive second-look laparotomy in epithelial ov...
23891404 - Recurrence patterns after resection of soft tissue sarcomas of the chest wall.
25487524 - Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer af...
23838904 - Induction of a pathological complete response by four courses of neoadjuvant chemothera...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oncogene     Volume:  25     ISSN:  0950-9232     ISO Abbreviation:  Oncogene     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-16     Completed Date:  2006-03-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8711562     Medline TA:  Oncogene     Country:  England    
Other Details:
Languages:  eng     Pagination:  981-9     Citation Subset:  IM    
Department of Molecular Pharmacology, Institut Paoli-Calmettes, UMR599 Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Proteins / analysis*
Breast Neoplasms / drug therapy*,  pathology,  surgery
Chemotherapy, Adjuvant
Middle Aged
Neoplasm Metastasis
Postoperative Period
Protein Array Analysis
Reg. No./Substance:
0/Blood Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/...
Next Document:  Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expre...